Sang Gyu is the founder and CEO of Novelty Nobility and a senior scientist with 25 years of experience in protein and antibody research. Up to now, he has designed more than 200 antibodies and achieved hands-on knowhow in immunization and affinity maturation, which became the impetus of Novelty Nobility’s pipeline development. Sang Gyu is an incumbent professor of Pharmacy at Ajou University and received a Ph.D. in Pharmacy from Seoul National University. He currently serves as an editorial board member of Scientific Reports.

Jin leads finance and business activities at Novelty Nobility. He is an experienced professional in fundraising, deal making and operations at a biotech company and is skillful at translating science into business, and vice versa. At Novelty Nobility, Jin is mostly interested in building a corporate culture that woos talented and decent people, while he himself spends most of the time in crunching numbers and reviewing contracts. He received an MBA from MIT Sloan School of Management.

Chan-Hee serves as Chief Scientific Officer of Novelty Nobility, where he bridges rigorous science with real-world market needs. He spent three decades at JW Group, where he led R&D innovation as CTO and served as CEO of affiliated companies, including JW C&C Research Labs and JW Creagen. Previously, he earned his Ph.D. from the College of Pharmacy at Seoul National University and began his professional journey at LG Chem’s Biotech Research Institute. Throughout his career, he has focused on translating early scientific discoveries into clinically meaningful strategies. His approach is guided by a simple philosophy: “The Market is the Compass, and Science is the Vessel.” Outside the lab and the boardroom, Chan-Hee enjoys a wide range of music and good coffee.

Seungjae serves as the CMO of Novelty Nobility, bringing a rare combination of academic depth and industry leadership to the role. He graduated from Yonsei University College of Medicine and completed his residency in ENT. In 2016, Seungjae began his industry career at Novartis Korea as Medical Director across the cardio-metabolic, respiratory, and neuroscience franchises. He then joined Hanmi Pharmaceuticals as CMO, where he led the clinical development of innovative medicines. Alongside his industry career, Seungjae has maintained a strong academic footprint and currently serves as Dean of the Graduate School of Health Science and Technology at UNIST. His motto is "connecting the dots" and "no experience is worthless".

YK serves as the CFO of Novelty Nobility. An Economics graduate from UC Berkeley, he brings a unique blend of global investment banking expertise and industrial management experience. By bridging capital market insights with hands-on corporate planning, YK is focused on driving sustainable growth and long-term value for the company. Outside the office, he is a devoted fan of LG Twins and loves visiting Jamsil Stadium to immerse himself in the excitement of the game and the roaring passion of the fellow supporters.

Gong is a biopharmaceutical expert with around two decades of experience in CMC development of antibody and protein therapeutics. Previously at Dong-A ST and CKD, he led the development of biosimilar products of second-generation EPO and wet AMD treatment, with a responsibility to submit product approval data to the South Korean regulatory authority (MFDS). He received a master’s degree from Sungkyunkwan University and is currently pursuing a doctorate degree at its graduate school. In his words, all projects currently underway at Novelty Nobility under his name are expected to be “SUCCESS”, which is what his Korean name Gong Sung means in English.

Taeyoung earned her Ph.D. in pathophysiology from the College of Pharmacy, Seoul National University and completed her postdoctoral training at the Seattle Children's Hospital. She has published dozens of scientific papers across various research fields that have accumulated well over 2,000 citations. Based on Taeyoung’s robust background as a research scientist, she is currently leading our Ophthalmology Research Department. While her passion for research means that she can usually be found in the lab, she also makes time to maintain a healthy work-life balance with family and friends.

Arlo directs business development and operations for Novelty Nobility’s US headquarters in Boston, Massachusetts. A chemist and PhD pharmacologist by training, Arlo has blended his science background with an entrepreneurial spirit to start and build several biotech companies over his 20-year career. His experience has included working with products across the entire development cycle from the R&D bench all the way to NDA submission readiness and commercial sale. Outside the office Arlo enjoys biking, hiking, and exploring New England with his wife and two daughters.